Equity Overview
Price & Market Data
Price: $87.40
Daily Change: +$0.90 / 1.03%
Daily Range: $85.60 - $89.28
Market Cap: $6,991,915,008
Daily Volume: 1,045,606
Performance Metrics
1 Week: 4.02%
1 Month: 23.55%
3 Months: 35.90%
6 Months: 106.4%
1 Year: 133.6%
YTD: 12.32%
Company Details
Employees: 188
Sector: Health technology
Industry: Biotechnology
Country:
Details
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis. The company also develops STAT6, a type 2 inflammation in allergic and atopic diseases; and TYK2 to treat autoimmune and inflammatory diseases. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside of the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.